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 10 
Abstract  11 
Isothermal titration calorimetry (ITC) was utilised to investigate suitability of the technique to determine 12 
the stoichiometry and thermodynamics of the interactions that occur between a commonly used chemotherapeutic 13 
drug, namely doxorubicin, and a polymer bead-based drug delivery embolisation system (DC Bead™). Six 14 
temperatures were selected for drug-polymer titrations (293 to 313 K) and in all cases an initially exothermic signal 15 
reverted to an endothermic response upon the saturation of the beads with drug. From these experiments, and 16 
subsequent calculations, the molar ratio of drug to SO3- (polymer) was found to be 0.4:1 at all temperatures studied. 17 
Enthalpic data was calculated from the raw ITC data with an average enthalpy of drug-polymer binding of – 14.8 18 
kJmol-1 at 293 K through to – 19.4 kJmol-1 at 313 K implying the process is enthalpically-driven yet only affected by 19 
an increase in experimental temperature to a limited extent whereby an increase in experimental temperature results 20 
in a small increase in the negativity in change in enthalpy recorded. The application of ITC in this study (with its 21 
unique ability to monitor real-time interactions and facilitate stoichiometric calculations) resolves the lack of 22 
knowledge regarding the thermodynamics of this specific drug-polymer interaction. This study confirms that ITC is 23 
not only useful for this specific system, but also highlights the potential use of ITC for more general studies in this 24 
area.  25 
 26 
Introduction  27 
Doxorubicin is a highly potent anticancer drug, widely used in chemotherapy for the treatment of various 28 
types of cancers such as Kaposi’s sarcoma, ovarian carcinoma and breast cancer (Rana et al., 2011). Despite a high 29 
degree of anti-tumour activity, drug resistance and strong adverse effects limit its efficacy. To overcome this 30 
problem several delivery strategies have been developed such as solid lipid nanoparticles and nanoliposomal 31 
delivery systems, for example Doxil® (Natarajan et al., 2014). Ion-exchange microspheres and, in particular, drug-32 
eluting beads, have become the system of choice for drug delivery (Liu et al., 2001; Shuhendler et al., 2010). For 33 
over a decade transarterial chemoembolisation using drug eluting beads (DEBs) has been a treatment option for 34 
primary and secondary liver cancers. These drug/device combination microspheres are delivered intra-arterially into 35 
tumour-feeding vessels to occlude blood flow, locally delivering a controlled and sustained therapeutic dose and 36 
reduced systemic exposure of cytotoxic cancer drugs (Kerr, 1987). Interactions between the drug and these more 37 
recently developed delivery systems is of interest for several reasons, primarily as it is important to fully 38 
characterise such formulations to help optimise their bioavailability for the patient. However, the self-association of 39 
the drug in aqueous solutions complicates the interpretation of the binding of drug with excipient, which may 40 
subsequently affect the release from the carrier (Agrawal et al., 2009; McLennan et al., 1985; Menozzi et al., 1984). 41 
One particular device that has shown success in the delivery of doxorubicin (Dox) is the DEB known as the DC 42 
Bead™, which is used for the treatment of hypervascular tumours and arteriovenous malformations (Lewis et al., 43 
2007; Lewis et al., 2006; Taylor et al., 2007). The beads consist of a biocompatible polyvinyl alcohol (PVA) 44 
hydrogel microsphere that has been modified with hydrophilic 2-acrylamido-2-methylpropane sulfonate sodium salt 45 
moieties (AMPS), and is tinted blue to allow visualisation of drug loading (Lewis and Dreher, 2012; Lewis et al., 46 
2007; Lewis et al., 2006). The negatively charged sulfonate group enables the bead to complex with positively 47 
charged drugs (Gonzalez et al., 2008). The beads are non-degradable and available in a range of sizes from 70-700 48 
µm. These are supplied steam sterilised in a 10 mL colour-coded glass vial sealed with a rubber stopper and 49 
aluminium cap. Each vial contains 2 mL of beads stored in 6 mL of phosphate buffered saline (PBS) and is intended 50 
for single patient use. The size of the bead and the amount of the drug is selected according to the pathology of the 51 
patient receiving treatment by a physician with appropriate experience in interventional oncology. The first size of 52 
DC Bead™ to be evaluated in a clinical study was 500-700 µm and was based upon the predicate Gelfoam particles. 53 
Gradually the size of DEBs has decreased, as smaller beads are favoured to achieve deeper tumour penetration and 54 
increase the delivery of drug as a result of a larger bead surface area to volume ratio. This has led to the 55 
development of 70-150 µm beads to meet the desire to deliver a large concentration of drug at a greater distal level 56 
whereupon the drug is taken up by the bead through an ion-exchange mechanism (Gonzalez et al., 2008; Lewis et 57 
al., 2007). When mixed with drug the beads change colour, which indicates the drug has been loaded. The beads 58 
have a high water content of > 95 % which enables the diffusion of molecules into and out of the polymer structure. 59 
Elution rate and uptake of the drug is dependent upon bead size, as diffusion is inversely proportional to bead size as 60 
caused by the increase in surface area to volume ratio. The beads initially increase in diameter as they are 61 
reconstituted in water, but then decrease as water is displaced from the bead and the drug is sequestered from the 62 
solution (Taylor et al., 2007). The ion-exchange mechanism is a reversible reaction and upon contact with ions 63 
contained in blood, the drug is released from the bead. DC Bead™ can be loaded with a recommended dose of 37.5 64 
mg Dox/mL of hydrated bead, however generally a dose of 25 mg Dox/mL of beads is administered. Typically 2-4 65 
mL is administered over a course of treatment, with a maximum of 150 mg of Dox per patient according to systemic 66 
dose limits. Understanding the interaction of drug with the aforementioned polymeric carrier will allow optimisation 67 
and modification of the design of a new type of drug delivery system for even more effective targeted drug therapy. 68 
To achieve an understanding of the stoichiometry and thermodynamics of the drug-bead interactions requires the 69 
application of a technique that can monitor binding phenomena in real-time and at specified temperatures. 70 
Isothermal titration calorimetry has the potential to achieve this aim.  71 
Isothermal titration calorimetry (ITC) is an established analytical technique used to investigate 72 
thermodynamic information for a variety of chemicals and biological systems. ITC has previously been used to 73 
investigate similar processes, such as polymer complexes (Zhang et al., 2015), drug-polymer interactions, surfactant 74 
behaviour and drug-excipient ratios (Waters et al., 2010). More specifically, ITC has been employed to evaluate 75 
intermolecular interactions with high sensitivity to establish the degree to which excipients become saturated with 76 
drug, i.e. maximum drug loading capabilities (Waters et al., 2012; Waters et al., 2014). ITC is ideally suited to such 77 
studies as it allows rapid and accurate determination of thermodynamic parameters such as binding constant (K), 78 
reaction stoichiometry (N), enthalpy (∆H), entropy (∆S) and Gibbs free energy (∆G) for any given system. Based on 79 
previous research within the group it was anticipated that ITC could be applied to the study of drug-polymer 80 
interactions to yield thermodynamic and stoichiometric data that cannot be measured using any other current 81 
analytical technique. Thus, this specific drug-polymer combination was identified as a model system to exemplify 82 
the applicability of the technique to such scenarios.  83 
This paper describes the stoichiometric and calorimetric interactions between doxorubicin and the DC 84 
Bead™ system at six specific temperatures to help identify the drug loading capacity of the systems under varying 85 
conditions and the thermodynamics associated with the binding process.  86 
 87 
Materials and Methods  88 
Doxorubicin HCl (Hisun, China) and DC Bead™ of size 70 – 150 µm (DC BeadM1™) were kindly 89 
donated by Biocompatibles UK Ltd, a BTG International group company (Camberley, UK), the latter supplied 90 
sterile in sodium phosphate buffer as a 2 mL hydrated volume. This particular bead size was chosen for this study as 91 
a model system as it was important to focus on one specific size range to minimise the variables encountered, 92 
furthermore, it has the maximum surface area to volume ratio thus it was anticipated that it would undergo the most 93 
rapid diffusion of drug through the bead. Buffer was removed and the beads were washed with deionised water then 94 
centifuged for 30 seconds at 3000 rpm prior to analysis. A Microcal isothermal titration calorimetric unit (ITC) 95 
linked to a Microcal MCS observer was utilised for all experiments with Origin software for analysis. Initial dilution 96 
experiments were conducted with the enathlpy of dilution for the addition of solvent to polymer subtracted from the 97 
total enthalpies of reaction to remove dilution effects. The sample cell (total volume = 1.42 mL) comprised of an 98 
aqueous solution containing 10 – 100 mg of beads with water (without buffer present) alongside a simple aqueous 99 
solution in the reference cell. The 290 μL syringe contained 10 mM doxorubicin (58 mg/mL) and was stirred at 307 100 
rpm, injecting a total of 14 injections at 20 μL per injection and 600 seconds between injections. These parameters 101 
were chosen as they were found to give an appropriate signal. Experiments were conducted at six temperatures (293 102 
to 313 K), all in triplicate to ensure reproducibility. The six temperatures were selected to cover typical room 103 
temperatures encountered during sample preparation (i.e. prior to injection) through to a temperature just beyond 104 
that encountered by the formulated product in vivo. Data were analysed to determine the stoichiometry of the drug-105 
polymer interaction (n) and enthalpy of binding (∆H) associated with the interaction highlighted in Figure 1.  106 
 107 
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DC Bead™     Doxorubicin Hydrochloride 113 
 114 
 115 
 116 
 117 
 118 
 119 
 120 
 121 
 122 
 123 
     Doxorubicin Loaded DC Bead™ 124 
Figure 1: Structural formula of DC Bead™, Doxorubicin and the combined product.  125 
 126 
Results and Discussion  127 
After experimenting with several drug concentrations it was found that 10 mM doxorubicin produced the 128 
most suitable ITC profile for injection, although a small demicellisation event was observed which then had to be 129 
· HCl
subtracted prior to further analysis. In contrast to this, the addition of aqueous solution to the sample cell containing 130 
the beads appeared to be almost thermoneutral. Initially the enthalpic signal indicated the process of drug-polymer 131 
binding to be an exothermic event, followed by endothermic demicellisation once the polymer had become saturated 132 
with drug (Figure 2). The inflection point can clearly be seen after the first few injections indicating saturation of the 133 
polymer had been achieved. In summary, the process observed in Figure 2 is assumed to be an initial drug-polymer 134 
(exothermic) binding event for approximately the first ten injections, culminating in bead saturation, followed by 135 
four drug demicellisation (endothermic) injections.  136 
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Figure 2: Raw ITC data for the injection of doxorubicin to aqueous solution at 298 K.  138 
 139 
Similar profiles to Figure 2 were observed at all temperatures studied. Assuming each experiment 140 
contained 100 mg of centrifuged beads (which are known to have a solid content of 3.03 %), which in turn is known 141 
to contain 45.45 % 2-acrylamido-2-methylpropane sulfonate (AMPS), then it was possible to calculate the ratio of 142 
drug to SO3- groups. It is assumed that the endpoint of exothermic signals was equivalent to when Dox saturated 143 
AMPS binding sites. The volume of Dox titrated to achieve the exothermic endpoint was calculated by multiplying 144 
the number of exothermic injections by the volume per injection (µL). The concentration of Dox (mg/µL) was then 145 
multiplied by the volume of injections at the endpoint (µL), to equal the mass of Dox at the said endpoint (mg). 146 
Since the mass of Dox had been calculated and the relative molecular mass is known ((C27H29NO11.HCl) 579.99g), 147 
the number of moles was calculated by dividing the mass of Dox bound to AMPS by the relative molecular mass of 148 
Dox. The solid mass of beads in the sample cell was the weight of centrifuged beads used (mg) divided by 100 and 149 
multiplied by the % solid content. However, Dox binds to AMPS groups’ situated on the beads and not to the whole 150 
bead structure. Each bead contains 45.45 % AMPS therefore, the mass of AMPS is equal to the mass of beads (mg) 151 
divided by 100 and multiplied by 45.45 %. Since the mass of AMPS has been calculated and the relative molecular 152 
mass is known ((C7H12NNaO4S) 229.23g), the number of moles can be calculated by dividing the mass of AMPS by 153 
the relative molecular mass of AMPS. Therefore moles of AMPS in the sample cell divided by the moles of Dox at 154 
the endpoint equals the molar ratio of Dox binding to AMPS. A summary of the calculated data can be seen in Table 155 
1 with an overall standard deviation of 0.02.  156 
Table 1: A summary of calculated binding ratios from ITC data for the injection of doxorubicin into polymer beads 157 
over a series of temperatures.  158 
Temperature / K Average no. Dox. per AMPS (± 0.02) 
293 0.39  
298 0.38 
303 0.37 
308 0.36 
310 0.37 
313 0.38 
 159 
This is the first report of the investigation of the interaction of soluble drug and immobilised sulfonate on a 160 
bead resin, yet similar reports have considered other drug-excipient interactions, for example, Yousefpour and co-161 
workers have used ITC to characterise the thermodynamic profile of doxorubicin-dextran interactions (Yousefpour 162 
et al., 2011). Thermal analysis of Dox-dextran complexation revealed that each Dox molecule bound with 3 dextran 163 
glycosyl monomers. In addition, Tian and co-workers characterised the binding of Dox with various types of 164 
pluronic-based co-polymer systems using ITC. Results revealed the strong electrostatic interactions between the –165 
COOH group of pluronic-PAA with the positively charged doxorubicin at physiological pH (Tian et al., 2007a). ITC 166 
showed clearly the pH effect on the Dox-polymer binding. The electrostatic interactions were found to be the 167 
predominant factor for the Dox/pluronic-PAA complex formation, while the shielding effect of NaCl on the 168 
positively charged amino group and negatively charged COOH decreased the strength of interactions (Tian et al., 169 
2007b). It is thought that a similar interaction is being observed in this study, i.e. the drug is forming a complex with 170 
the SO3- groups within the polymer. The lack of significant variation in ratio with temperature implies there is no 171 
temperature-induced conformational change in the polymer in solution resulting in a change in the number of 172 
‘available’ SO3- groups. This may not be overly surprising, as the bead matrix is cross-linked and polymer chain 173 
rearrangement will be restricted.  174 
Through analysis of the area under the curves for the data presented (and their replicates) up to the points of 175 
inflection permitted determination of the change in enthalpy associated with the binding event to be determined, as 176 
summarised in Table 2.  177 
 178 
 179 
 180 
 181 
Table 2: A summary of calculated changes in enthalpy upon binding from ITC data for the injection of doxorubicin 182 
into polymer beads over a series of temperatures.  183 
Temperature / K Average change in enthalpy upon dox.- bead binding 
(kJ/mol) 
293 - 14.8 (± 2.4) 
298 - 15.9 (± 2.5) 
303 - 15.8 (± 0.4) 
308 - 17.8 (± 0.7) 
310 - 21.4 (± 3.1) 
313 - 19.4 (± 1.3) 
 184 
For binding at 293 K the mean enthalpy change was found to be – 14.8 kJmol-1 whereas at 313 K was – 185 
19.4 kJmol-1. Although small differences were observed between the temperatures, overall the binding phenomenon 186 
was not dramatically affected by an increase in experimental temperature of 20 K. When these values are compared 187 
with data for interactions of a similar nature, such as diminazene aceturate with poly(aspartic acid), it can be 188 
confirmed that the values obtained in this work correspond well (Govender et al., 2000), whereby the authors state 189 
the interaction was identified to be enthalpically-driven through the formation of hydrogen bonds. Furthermore, the 190 
same thermodynamic conclusion can be drawn, in that the high enthalpy change of reaction compensates for a small 191 
entropic change with the additional observation that the process is only affected by temperature over the range 192 
studied to a small extent. Although in some cases it would appear there are small differences between the values, 193 
once the error limits are included the actual change in enthalpy can be considered to be almost constant. Any minor 194 
differences that have been recorded are most likely a result of small rearrangements of surrounding solvent 195 
molecules rather than as a direct result of variations in drug-bead interactions. 196 
However, the findings from this study were not as straightforward as initially expected when considering 197 
the drug to polymer ratio values obtained. Data obtained from previous work on the same drug-bead system (using 198 
UV analysis) has demonstrated binding of 37.5 mg per mL of bead, which equates to a Dox:AMPS ratio of 0.7:1 199 
(and is unanimously accepted as an achievable value in clinical practice equating to 150 mg in 4 mL of beads, i.e. 200 
the standard recommended dose per administration for patients per treatment). Indeed, ratios of 1:1 are also 201 
achievable with higher doxorubicin loading concentrations (Fajardo, 2006), whereas in this study, the ratio was 202 
closer to 0.4:1. The difference between these two ratios is most likely a result of differing methods of mixing, the 203 
clinical approach routinely involves the complete, rapid addition of drug to bead whereas the ITC method is small, 204 
sequential additions. This alternative, latter approach may induce conformational changes within the beads that 205 
prevent further drug accessing the binding sites, keeping the ratio lower than that observed using UV analysis.  206 
 207 
Conclusions  208 
 In summary, this study has determined the suitability of ITC to investigate drug-excipient interactions such 209 
as those between drugs and polymer beads. Moreover, it has been possible to calculate the ratio of drug molecules to 210 
SO3- groups which appears to be temperature independent and the change in enthalpy with binding is also unaffected 211 
by temperature effects. The reasons for differences between the results presented here and UV data are the subject of 212 
current research. Finally, it would be of interest to investigate the same bead system with a series of compounds to 213 
determine the specificity of the binding process, such as that observed by others for related polymer-drug systems 214 
(Govender et al., 2000). To maximise the efficiency of drug delivery systems, such as those studied in this work, it is 215 
essential to fully understand their physicochemical behaviour and then, based on this knowledge, it may be possible 216 
to enhance the amount that can be contained within the polymer by maximising drug-polymer interactions. Although 217 
the experimental protocol was somewhat dissimilar to that seen in clinical applications, i.e. small aliquots were 218 
added over many hours rather than the standard mixing time of 30 minutes prior to injection, it still yields useful 219 
information with respect to drug-bead interactions. 220 
 221 
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